Claude Lemarie

Claude Lemarie

Auto-generated profile, based on publicly available information

Claude Lemarie

Cell Therapy Facility, Institut Paoli Calmettes, Marseille, France

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2005 in Transfusion
Verified
Journal Article
Closed access
PDF file
CLClaude Lemarie
Claude Lemarie
BCBoris Calmels
Boris Calmels
CMCarine Malenfant
Carine Malenfant
VAVérane Arneodo
Vérane Arneodo
DBDidier Blaise
Didier Blaise
CCChristian Chabannon
Christian Chabannon

5 March 2007 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
CLC Lemarie
C Lemarie
BEB Esterni
B Esterni
BCB Calmels
B Calmels
BDB Dazey
B Dazey
VLV Lapierre
V Lapierre
GMG Michel
G Michel
Cord blood (CB) units are increasingly used for allogeneic transplantation. Cell dose, a major factor for CB selection, is evaluated before freezing by each CB bank, using various techniques. This may introduce variability and affect the prediction of cell recovery after thawing, or haematopoietic reconstitution. Forty-two children were transplanted at the same institution with unrelated CB units. All units were thawed and evaluated at the same cell therapy facility, using standard procedures. We investigated: (i) factors that affect cell loss after thawing, and (ii) the importance of CD34+ cell doses. Prefreeze and post-thaw CD34+ cell doses were statistically correlated, thus suggesting that variability in numeration techniques used by different CB banks does not compromise the biological and clinical value of these figures. CD34+ cell recovery appeared to be correlated with the absolute number of CD34+ cells per frozen bag. Infused CD34+ is the cell dose that better correlates with platelet reconstitution delay; in addition, when using a quartile comparison, haematopoietic recovery appeared to be related with prefreeze and post-thaw CD34+ cell doses. We conclude that enumeration of CD34+ cells in CB units is of biological significance, and may help select CB units and identify patients at risk of delayed recovery.

1 November 2016 in Bulletin du Cancer
Verified
Journal Article
Closed access
SNStéphanie Nguyen
Stéphanie Nguyen
Yves ChalandonYves Chalandon
Yves Chalandon
CLClaude Lemarie
Claude Lemarie
SSSophie Simon
Sophie Simon
DMDominique Masson
Dominique Masson
MRMarie-Thérèse Rubio
Marie-Thérèse Rubio

1 December 2017 in Cytotherapy
Verified
Journal Article
Open access
BMBechara Mfarrej
Bechara Mfarrej
GBGuillaume Bouchet
Guillaume Bouchet
JCJérôme Couquiaud
Jérôme Couquiaud
LRLionel Regimbaud
Lionel Regimbaud
SBSteven Binninger
Steven Binninger
BCBoris Calmels
Boris Calmels
Cryopreserved hematopoietic progenitor cell (HPC) grafts are widely infused to patients with malignant and nonmalignant conditions. Despite reduction of immediate side effects linked to dimethyl sulfoxide (DMSO), cell debris-containing grafts and comparable hematopoietic engraftment between washed and unwashed cryopreserved products, bedside infusion of thawed HPC grafts is still preferred. Introduction of automated devices is important for standardization and consistency of graft manipulation. Additionally, these techniques are likely to be useful for the delivery of innovative cell-based medicinal products that are currently under development. In this study, we evaluated three consecutive versions of the Lovo device (Fresenius Kabi) for automated washing of thawed HPC products. A total of 42 HPC products intended for destruction were used. Measured outcomes included viable CD34+ cell recovery, viability, total processing time and post-washing stability. Preliminary data using the prototype Lovo 0.0 to process a single HPC unit showed better recovery and viability of CD34+ cells using a two-cycle than a three-cycle wash, with >95% DMSO elimination. The Lovo 1.0 performed equally well. When simultaneously processing two HPC units, the upgraded Lovo 2.0 device demonstrated comparable CD34+ recovery, DMSO elimination efficiencies and time-saving capacity. Furthermore, washed cell products were stable for 4 hours at room temperature. Lovo device satisfies clinically relevant issues: ability to efficiently wash two HPC units simultaneously and compatibility with transport to nearby transplantation centers.

10 January 2007 in Journal of Immunological Methods
Verified
Journal Article
Closed access
CLClaude Lemarie
Claude Lemarie
RSRomina Sugaye
Romina Sugaye
IKIndreshpaul Kaur
Indreshpaul Kaur
TTTim Taga
Tim Taga
CCChristian Chabannon
Christian Chabannon
JMJohn Mcmannis
John Mcmannis

1 May 2014 in médecine/sciences
Verified
Journal Article
Open access
PDF file
CCChristian Chabannon
Christian Chabannon
FSFlorence Sabatier
Florence Sabatier
EREmmanuelle Rial-Sebbag
Emmanuelle Rial-Sebbag
BCBoris Calmels
Boris Calmels
JVJulie Veran
Julie Veran
AMAurélie Mahalatchimy
Aurélie Mahalatchimy
Regulation (EC) n° 1394/2007 from the European Parliament and the Council describes a new category of health products termed « Advanced Therapy Medicinal Products » (ATMPs). ATMPs derive from cell engineering, tissue engineering or genetic manipulations, and can in some instances be combined with medical devices. ATMPs are distributed and administered to patients, after biotechnology or pharmaceutical companies have obtained a marketing authorization that is granted by the European Commission on the basis of the European Medicines Agency (EMA) assessment. Seven years after the publication of the regulation, few of these therapies have received a marketing authorization, and even fewer have met commercial success, suggesting that a number of medical and economic issues still need to be sorted out in order to achieve sustainability in this field. The coexistence of three sets of rules for three categories of health products that are biologically and medically related - ATMPs, ATMPs produced under the hospital exemption rule, and cell therapy products (CTPs) (a specific legal category in France) that have long been used in hematopoietic cell transplantation - constitutes a complex regulatory framework. This situation raises significant issues for historical as well as emerging operators in this moving field that are discussed thereafter.